Celsentri (maraviroc)
- Region
- 🇪🇺 EU
- Active substance
- maraviroc
- Company
- ViiV Healthcare B.V.
- Status
- Authorised
- Therapeutic area
- HIV Infections
- CHMP opinion
- Thu 19 Jul 2007
- EU approval
- Tue 18 Sep 2007
- Application
- EMEA/H/C/000811
- ATC
- J05AX09
- Official record
- www.ema.europa.eu
Indication
Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable
Regulatory milestones
No milestones recorded in the last year.
Follow Celsentri
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.